Don Dizon, FACP, FASCO, MD, Brown University, Providence, RI, describes the latest developments in using precision therapy for ovarian cancer. Access to precision therapy has greatly expanded beyond patients with BRCA mutations, and novel research has suggested maintenance PARP inhibitors can result in durable responses, especially in patients with BRCA-positive ovarian cancer. This interview took place at the 7th Annual Practical Recommendations in Immuno and Molecular Oncology Meeting (PRIMO 2022).